Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Analyte peptide sequences, fragment ions and fragmentation collision energy used for quantitation of ocrelizumab.

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Quantitation Assay, Sequencing

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Ocrelizumab serum concentrations in three patients with MS, undergoing treatment with ocrelizumab. Error bars display ± one standard deviation. Cmax concentrations were 243 (gray), 220 (red) and N/A (blue) µg/mL. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Standard Deviation

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Extracted-ion chromatogram of ocrelizumab quantifier (blue) and qualifier (red) ions from analyzing the lowest standard concentration versus a blank serum sample (black). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Concentration Assay

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Calibration curve of measured LC-MS/MS response to spiked ocrelizumab concentration in blank serum (n = 3). Precision and accuracy are presented in table 2.

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Liquid Chromatography with Mass Spectroscopy, Concentration Assay

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Total variation for quantitation of ocrelizumab (n = 12, days = 6).

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Quantitation Assay

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Within-run variation for quantitation of ocrelizumab (n = 6).

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Quantitation Assay

Journal: Journal of Mass Spectrometry and Advances in the Clinical Lab

Article Title: Ocrelizumab quantitation by liquid chromatography-tandem mass spectrometry

doi: 10.1016/j.jmsacl.2022.07.004

Figure Lengend Snippet: Structure of rituximab in complex with CD20 (PDB entry 6VJA). Heavy chain in orange, light chain in red, CD20 in blue. (a) Alignment-based, structural location of the signature peptide (green) used for quantitation of ocrelizumab. (b) Sequence variations between rituximab and ocrelizumab within 6 Å to CD20, marked with spheres. Mutations from rituximab to ocrelizumab lcT92S, lcS93F, hcS95V, hcG98S, hcG99N and an extra S residue after position hc99 in ocrelizumab. Figures are generated using PyMol. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: The protein sequence of ocrelizumab was obtained from Inxight Drugs .

Techniques: Quantitation Assay, Sequencing, Residue, Generated

Journal: Journal of Neurology

Article Title: Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases

doi: 10.1007/s00415-010-5876-x

Figure Lengend Snippet: Illustration of Reibergrams for all patient groups. Q–IgG, Q–IgA, and Q–IgM are indicated in relation to the CSF–blood barrier function, represented by Q alb. For interpretation of the Reibergrams, see Fig.

Article Snippet: Assessment of the mean quantity and frequency of intrathecal Ig synthesis, frequency of blood–CSF barrier dysfunction and Reibergrams were determined using the software “Protein Statistics in CSF Analysis with Reibergrams” (Version 3.0, COMED), which calculates quotients and the intrathecally synthesized fractions [IgX loc (m) or IgX IF (m)] with reference to the Q mean of the reference range.

Techniques: